1. Appan, S., Laurent, S., Chapman, M., et al. (1990). Growth and growth hormone therapy in hypochondroplasia. Acta Paediatrica Scandinavica, 79, 796–803.
2. Bellus, G. A., McIntosh, I., Szabo, J., et al. (1996). Hypochondroplasia: Molecular analysis of the fibroblast growth factor receptor 3 gene. Annals of the New York Academy of Sciences, 785, 182–187.
3. Blomberg, M., Jeppesen, E. M., Skovby, F., et al. (2010). FGFR3 mutations and the skin: Report of a patient with a FGFR3 gene mutation, Acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature. Dermatology, 220, 297–305.
4. Bober, M. B., Bellus, G. A., & Nikkel, S. M., et al. (2013). Hypochondroplasia. GeneReviews. Updated September 26, 2013. Available at:
http://www.ncbi.nlm.nih.gov/books/NBK1477/
5. Bonaventure, J., Rousseau, F., Legeai-Mallet, L., et al. (1996). Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism. American Journal of Medical Genetics, 63, 148–154.